I'm not advocating a new CEO. I would like for him to pressure JNJ to update the trial. lltinvest, I blame Manuso for the poor trial, because it was first designed on his shift. But at the time, CR and PR were crucial indicators of Dacogen working and little was understood about these drugs. I, also do not like that he use's forward looking statements and hasn't followed through on many.
But I do like the 10 items that I have listed and long term, those are the important ones.